Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Galloway

Showing results (291-300 of 303) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin ContraindicationJared Weiss, Siddharth Sheth, Allison M Deal, et al.
JAMA Oncology|December 23, 2016
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical TrialJoanne B Weidhaas, Jonathan Harris, Dörthe Schaue, et al.
Journal of the National Cancer Institute|September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2025
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer - Results from xxxxxChristina L Runge, Jessica A Lyness, Maura L Gillison, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 4, 2025
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical TrialsLaila A Gharzai, Emily Morris, Matthew J Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Science (New York, N.Y.)|May 20, 2008
Impacts of atmospheric anthropogenic nitrogen on the open oceanR A Duce, J LaRoche, K Altieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic CancerLi Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Cancer Causes & Control : CCC|March 11, 2021
The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer modelLeandro L Matos, Carlos Henrique Q Forster, Gustavo N Marta, et al.
Pageof 31

Showing results (291-300 of 303) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2020
Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin ContraindicationJared Weiss, Siddharth Sheth, Allison M Deal, et al.
JAMA Oncology|December 23, 2016
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical TrialJoanne B Weidhaas, Jonathan Harris, Dörthe Schaue, et al.
Journal of the National Cancer Institute|September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2025
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer - Results from xxxxxChristina L Runge, Jessica A Lyness, Maura L Gillison, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 4, 2025
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical TrialsLaila A Gharzai, Emily Morris, Matthew J Schipper, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Science (New York, N.Y.)|May 20, 2008
Impacts of atmospheric anthropogenic nitrogen on the open oceanR A Duce, J LaRoche, K Altieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic CancerLi Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Cancer Causes & Control : CCC|March 11, 2021
The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer modelLeandro L Matos, Carlos Henrique Q Forster, Gustavo N Marta, et al.
Pageof 31